ESMO guidelines in advanced NSCLC

2016

Rolf Stahel

University Hospital of Zürich

1 |

Seoul, 28.10.2016

ESMO clinical practice guidelines in metastatic non-

small cell lung cancer: Squamous cell carcinoma

2 |

Novello et al,

Ann Oncol 2016

ESMO clinical practice guidelines in metastatic non-

small cell lung cancer: Squamous cell carcinoma

3 |

Novello et al,

Ann Oncol 2016

Levels of evidence and grade of recommendation4 |

Adapted from the Infectious Diseases Society of America -United States Public Health Service Grading

System. Clin Infect Dis 2001;33:139 –144

Magnitunde of Clinical Benefit Scale: Form 2a

(primary endpoint OS, OS < 1 year, non-curative)

5 |

Cherny et al, Ann Oncol 2015

5

4

3

2

1

A

B

C

Curative Non-curative

Magnitunde of Clinical Benefit Scale: Second line

squamous cell carcinoma

6 |

ESMO clinical practice guidelines in metastatic non-

small cell lung cancer: Non-squamous cell carcinoma

7 |

Novello et al,

Ann Oncol 2016

ESMO clinical practice guidelines in metastatic non-

small cell lung cancer: Non-squamous cell carcinoma

8 |

Novello et al,

Ann Oncol 2016

Magnitunde of Clinical Benefit Scale: Second line

non-squamous cell carcinoma

9 |

ESMO clinical practice guidelines in metastatic

non-small cell lung cancer: Activating EGFR mutation

10 |

Novello et al,

Ann Oncol 2016

Magnitude of Clinical Benefit Scale;: Erlotinib and

bevacizumab for EFGR mutated NSCLC

11 |

ESMO clinical practice guidelines in metastatic non-

small cell lung cancer: Activating EGFR mutation

12 |

Novello et al,

Ann Oncol 2016

ESMO clinical practice guidelines in metastatic non-

small cell lung cancer: ALK translocation

13 |

Novello et al,

Ann Oncol 2016

KEYNOTE-024: Pembrolizumab vs platinum-based chemotherapyas first-Line therapy for advanced NSCLC with a PD-L1 TPS ≥50%Martin Reck,1 Delvys Rodríguez-Abreu,2 Andrew G. Robinson,3 Rina Hui,4 Tibor Csőszi,5 Andrea

Fülöp,6 Maya Gottfried,7 Nir Peled,8 Ali Tafreshi,9 Sinead Cuffe,10 Mary O’Brien,11 Suman Rao,12

Katsuyuki Hotta,13 Melanie A. Leiby,14 Gregory M. Lubiniecki,14 Yue Shentu,14 Reshma Rangwala,14 and

Julie R. Brahmer15on behalf of the KEYNOTE-024 investigators

14 |

KEYNOTE-024: Pembrolizumab vs platinum-based chemotherapyas first-Line therapy for advanced NSCLC with a PD-L1 TPS ≥50%Martin Reck,1 Delvys Rodríguez-Abreu,2 Andrew G. Robinson,3 Rina Hui,4 Tibor Csőszi,5 Andrea

Fülöp,6 Maya Gottfried,7 Nir Peled,8 Ali Tafreshi,9 Sinead Cuffe,10 Mary O’Brien,11 Suman Rao,12

Katsuyuki Hotta,13 Melanie A. Leiby,14 Gregory M. Lubiniecki,14 Yue Shentu,14 Reshma Rangwala,14 and

Julie R. Brahmer15on behalf of the KEYNOTE-024 investigators

15 |

Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in advanced NSCLCFabrice Barlesi, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish Gadgeel, Toyoaki

Hida, Dariusz Kowalski, Manuel Cobo Dols, Diego Cortinovis, Joseph Leach, Jonathan Polikoff, David

R. Gandara, Carlos Barrios, Daniel Chen, Pei He, Marcin Kowanetz, Marcus Ballinger, Daniel

Waterkamp, Alan Sandler, Achim Rittmeyer

16 |

Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in advanced NSCLCFabrice Barlesi, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish Gadgeel, Toyoaki

Hida, Dariusz Kowalski, Manuel Cobo Dols, Diego Cortinovis, Joseph Leach, Jonathan Polikoff, David

R. Gandara, Carlos Barrios, Daniel Chen, Pei He, Marcin Kowanetz, Marcus Ballinger, Daniel

Waterkamp, Alan Sandler, Achim Rittmeyer

17 |

18 |

ETOP | Name Project | Title Presentation | Zurich, July 27, 2009